"Uzbekistan Pharmaceuticals & Healthcare Report Q1 2013" Is Now Available at Fast Market Research
BMI View: We maintain the view that risk-averse pharmaceutical, healthcare and medical device companies should avoid Uzbekistan. While the country has a definite need for pharmaceuticals and medical devices, the regulatory environment remains opaque and state-dominated. Moreover, the government is committed to boosting Uzbekistan's domestic capacity for pharmaceutical manufacturing, which is expected to gradually decrease market potential for most generic medicines.
View full press release